| Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a … H Wilke, K Muro, E Van Cutsem, SC Oh, G Bodoky, Y Shimada, ... The lancet oncology 15 (11), 1224-1235, 2014 | 2601 | 2014 |
| Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo … CS Fuchs, J Tomasek, CJ Yong, F Dumitru, R Passalacqua, C Goswami, ... The Lancet 383 (9911), 31-39, 2014 | 2504 | 2014 |
| Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously … E Van Cutsem, J Tabernero, R Lakomy, H Prenen, J Prausová, ... Journal of Clinical Oncology 30 (28), 3499-3506, 2012 | 1726 | 2012 |
| ZD1839, a selective oral epidermal growth factor receptor–tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I … M Ranson, LA Hammond, D Ferry, M Kris, A Tullo, PI Murray, V Miller, ... Journal of Clinical Oncology 20 (9), 2240-2250, 2002 | 994 | 2002 |
| Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. DR Ferry, A Smith, J Malkhandi, DW Fyfe, PG deTakats, D Anderson, ... Clinical cancer research: an official journal of the American Association …, 1996 | 867 | 1996 |
| Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label … T Waddell, I Chau, D Cunningham, D Gonzalez, AFC Okines, ... The lancet oncology 14 (6), 481-489, 2013 | 844 | 2013 |
| Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial MT Seymour, TS Maughan, JA Ledermann, C Topham, R James, ... The Lancet 370 (9582), 143-152, 2007 | 738 | 2007 |
| Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin LW Seymour, DR Ferry, D Anderson, S Hesslewood, PJ Julyan, R Poyner, ... Journal of clinical oncology 20 (6), 1668-1676, 2002 | 578 | 2002 |
| Mitomycin, ifosfamide, and cisplatin in unresectable non–small-cell lung cancer: Effects on survival and quality of life MH Cullen, LJ Billingham, CM Woodroffe, AD Chetiyawardana, ... Journal of Clinical Oncology 17 (10), 3188-3194, 1999 | 572 | 1999 |
| Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study A Ohtsu, JA Ajani, YX Bai, YJ Bang, HC Chung, HM Pan, T Sahmoud, ... Journal of Clinical Oncology 31 (31), 3935-3943, 2013 | 558 | 2013 |
| Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial G Brown The Lancet Oncology 13 (11), 1152-1160, 2012 | 510 | 2012 |
| Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer S Danson, D Ferry, V Alakhov, J Margison, D Kerr, D Jowle, M Brampton, ... British journal of cancer 90 (11), 2085-2091, 2004 | 487 | 2004 |
| Cisplatin in the modern era: The backbone of first-line chemotherapy for non-small cell lung cancer DA Fennell, Y Summers, J Cadranel, T Benepal, DC Christoph, R Lal, ... Cancer treatment reviews 44, 42-50, 2016 | 386 | 2016 |
| Calcium channels: direct identification with radioligand binding studies H Glossmann, DR Ferry, F Lübbecke, R Mewes, F Hofmann Trends in Pharmacological Sciences 3, 431-437, 1982 | 382 | 1982 |
| Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer LW Seymour, DR Ferry, DJ Kerr, D Rea, M Whitlock, R Poyner, C Boivin, ... International journal of oncology 34 (6), 1629-1636, 2009 | 344 | 2009 |
| Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial SJ Dutton, DR Ferry, JM Blazeby, H Abbas, A Dahle-Smith, W Mansoor, ... The lancet oncology 15 (8), 894-904, 2014 | 336 | 2014 |
| Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non–small-cell lung cancer RB Natale, S Thongprasert, FA Greco, M Thomas, CM Tsai, ... Journal of Clinical Oncology 29 (8), 1059-1066, 2011 | 306 | 2011 |
| Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified … J Tabernero, E Van Cutsem, R Lakomý, J Prausová, P Ruff, GA Van Hazel, ... European journal of cancer 50 (2), 320-331, 2014 | 298 | 2014 |
| Clinical trials of P-glycoprotein reversal in solid tumours DR Ferry, H Traunecker, DJ Kerr European journal of cancer 32 (6), 1070-1081, 1996 | 285 | 1996 |
| Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised … CS Fuchs, K Shitara, M Di Bartolomeo, S Lonardi, SE Al-Batran, ... The Lancet Oncology 20 (3), 420-435, 2019 | 263 | 2019 |
Hartmut GlossmannFull Professor M.D. PhD. Qualified Specialist In Pharmacology,Toxicology and Clinical PharmacologyVerified email at i-med.ac.at
